53374-52-0

Basic information

• Product Name: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI)
• Synonyms: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI);4-NITROSO-3,4-DIHYDROQUINOXALIN-2(1H)-ONE
• CAS NO: 53374-52-0
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.16
• Product Categories: PIPERIDINE
• Mol File: 53374-52-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 447.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.48±0.1 g/cm3(Predicted)
• PKA: 12.20±0.20(Predicted)
• CAS DataBase Reference: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI)(53374-52-0)
• EPA Substance Registry System: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI)(53374-52-0)

Safety Data

• Hazardous Substances Data: 53374-52-0(Hazardous Substances Data)

Usage

Structure

A quinoxaline derivative with a nitroso group

Potential use

As a building block in the synthesis of various organic compounds

Biological activity

The nitroso group has potential biological activity

Interest in industries

Pharmaceutical and medicinal chemistry

Ongoing research

Further research and exploration into its properties and potential applications are being conducted.

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 7647-01-0 hydrogenchloride 
• 59564-59-9 1,2,3,4-tetrahydroquinoxalin-2-one 

Downstream Products

• 313368-91-1 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido-[3’,4’:4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 1187020-80-9 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt 
• 313368-95-5 4-((6bR,10aS)-3-benzyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 1576239-54-7 4-((6bR,10aS)-3-butyl-2,3,6b,9,10,10ahexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 313368-94-4 4-((6bR,10aS)-3-isopropyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 313368-93-3 4-((6bR,10aS)-3-ethyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 313368-92-2 4-((6bS,10aR)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one 
• 1576239-87-6 (6bR,10aS)-8-[(3-(4-fluorophenyl)-4,5-dihydroisoxazol-5-yl)methyl]-3-methyl-2,3,6b,7,8,9,10,10aoctahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline 
• 1576239-84-3 4-fluoro-N-[2-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)ethyl]benzamide 

Relevant articles and documents

ITI-007

A great deal has been achieved in the treatment of schizophrenia in recent decades, especially the treatment of the positive symptoms by targeting dopamine D2 receptors. But the disease has a range of other symptoms which gravely affect quality of life and which require other strategies or additional targets. Among the agents gradually filling the empty therapeutic space is ITI-007, which has an unusual mechanistic profile: it targets 5-HT2A and dopamine D2 receptors, but has a much higher affinity for the former receptors. This may allow the drug's effects to be modified by dose adjustments, with effects on sleep disturbances, depression and anxiety seen with lower doses and higher doses affecting the positive symptoms of schizophrenia through dopamine D2 receptor modulation. Higher doses can also inhibit serotonin transporters and produce glutamatergic modulation which could improve positive and negative symptoms, depressive symptoms and cognitive impairments. The findings of preclinical studies have supported this view of the drug, and a phase II study found effects on positive and negative symptoms with a safety profile distinct from atypical antipsychotics. Phase III investigation in schizophrenia has begun, and clinical investigation in insomnia and dementia is also under way.

FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE

This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4- b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.